MDGLHealthcare · BiotechnologyThe 17 Wall Street analysts covering Madrigal Pharmaceuticals, Inc. hold a median 12-month price target of $650 — +34.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 67 of 100 as at 1 Aug 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores Madrigal Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Volatility (93): The share price has been relatively steady.
Issuance (13): The company has been issuing shares or taking on financing, diluting existing holders.
The rank is the raw material. Whether the rules would actually own Madrigal Pharmaceuticals, Inc. — and when they’d sell — is the membership.
The bullish and bearish analyst opinions on MDGL, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +34.9% from it.
Of the 20 most recent actions, 1 moved their price target up and 2 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 3 Aug 2026 | Barclays | Maintains | Overweight | $964 → $962 |
| 29 July 2026 | Canaccord Genuity | Maintains | Buy | $578 → $587 |
| 27 July 2026 | Wells Fargo | Initiates | Overweight | $685 |
| 11 June 2026 | B of A Securities | Maintains | Neutral | — |
| 11 June 2026 | B of A Securities | Maintains | Neutral | $550 → $542 |
| 13 May 2026 | Truist Securities | Maintains | Buy | — |
| 7 May 2026 | Canaccord Genuity | Maintains | Buy | — |
| 7 May 2026 | Evercore ISI Group | Maintains | Outperform | — |
| 6 May 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 20 Feb 2026 | B of A Securities | Maintains | Neutral | — |
| 28 Jan 2026 | Barclays | Initiates | Overweight | — |
| 20 Jan 2026 | Citizens | Maintains | Market Outperform | — |
| 19 Dec 2025 | Piper Sandler | Maintains | Overweight | — |
| 11 Dec 2025 | B. Riley Securities | Maintains | Buy | — |
| 21 Nov 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 20 Nov 2025 | Oppenheimer | Maintains | Outperform | — |
| 19 Nov 2025 | Truist Securities | Maintains | Buy | — |
| 13 Nov 2025 | Canaccord Genuity | Maintains | Buy | — |
| 11 Nov 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 5 Nov 2025 | Cantor Fitzgerald | Upgrade | Overweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 98% of US stocks
Cheaper than 16% of US stocks
Cheaper than 4% of US stocks
Cheaper than 92% of US stocks
Higher than 91% of US stocks
Higher than 82% of US stocks
Higher than 96% of US stocks
Higher than 24% of US stocks
Higher than 14% of US stocks
Higher than 20% of US stocks
Higher than 21% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. MDGL appears on the weeks it earns a place.
Madrigal Pharmaceuticals beat Q2 estimates, driven by Rezdiffra sales which lifted revenues 71% year over year, but MDGL stock fell as investors weighed concerns about slower commercial growth.
Why it matters — The stock decline despite a quarterly beat highlights investor focus on the pace of Rezdiffra's commercial rollout, a key metric for MDGL's near-term prospects.
Madrigal Pharmaceuticals reported second-quarter 2026 net sales of $364.3 million for Rezdiffra, a 71% increase from a year earlier, driven by expanded patient numbers receiving its MASH treatment.
Why it matters — The significant sales growth for Rezdiffra signals expanding adoption of Madrigal's first-in-class MASH treatment, a key product for the company's future performance.
Madrigal Pharmaceuticals held its Q2 2026 earnings call, and Seeking Alpha published a transcript of the event.
Why it matters — Earnings call transcripts provide investors and analysts with management's detailed commentary on the company's quarterly financial performance and business outlook.
Madrigal Pharmaceuticals reported a second-quarter loss of $1.99 per share, which was narrower than the Zacks Consensus Estimate of a $2.55 loss, though wider than the $1.9 loss per share from the same quarter a year ago. Revenue for the quarter exceeded analyst expectations.
Why it matters — For MDGL watchers, the smaller-than-expected quarterly loss and revenue beat may indicate improving financial momentum relative to analyst forecasts.
Madrigal Pharmaceuticals announced its second-quarter 2026 financial results and provided corporate updates. The company continues to focus on developing novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH).
Why it matters — MDGL watchers would care because quarterly financial results and corporate updates offer insight into the company's progress with its MASH-focused pipeline and overall financial health.
The 17 Wall Street analysts covering Madrigal Pharmaceuticals, Inc. have a median 12-month price target of $650, with estimates ranging from $553 to $964. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 17 analysts covering Madrigal Pharmaceuticals, Inc., 15 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Madrigal Pharmaceuticals, Inc. 67 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 1 Aug 2026, Madrigal Pharmaceuticals, Inc. ranks 67 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (93 of 100).
No one can know that. What the data says: the median 12-month target from 17 analysts implies +34.9% from the last close, and Ticker Nerd's factor model ranks Madrigal Pharmaceuticals, Inc. 67 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Madrigal Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MDGL are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $553 to $964 over the next 12 months.
Madrigal Pharmaceuticals, Inc. returned +59.5% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), also known as non-alcoholic steatohepatitis (NASH), and related liver conditions.
The most recent item we track (Zacks Investment Research, 31 July 2026): "MDGL Stock Down Despite Q2 Beat, MASH Drug Drives Top-Line Y/Y Growth". Madrigal Pharmaceuticals beat Q2 estimates, driven by Rezdiffra sales which lifted revenues 71% year over year, but MDGL stock fell as investors weighed concerns about slower commercial growth.
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), also known as non-alcoholic steatohepatitis (NASH), and related liver conditions. Its lead product, Rezdiffra (resmetirom), is a liver-directed thyroid hormone receptor beta agonist approved for treating adults with MASH and moderate to advanced liver fibrosis, marking it as the first FDA-approved therapy in this category. The company has also expanded its pipeline through a global licensing agreement for ervogastat, an oral DGAT-2 inhibitor in Phase 2 development, to complement its MASH treatment offerings. Madrigal Pharmaceuticals, Inc. targets the growing demand in the metabolic liver disease market, where it plays a pioneering role with rapid commercialization efforts, including approvals in the United States and Europe. Headquartered in West Conshohocken, Pennsylvania, and founded in 2000, the company concentrates on addressing unmet needs in cardiovascular, metabolic, and liver diseases through targeted oral therapies.
CEO Mr. William J. Sibold · 915 employees · United States · https://www.madrigalpharma.com